Ovarian Cancer Risk and Survival in BRCA1/2 Carriers
Annual rept. 1 Sep 2001-31 Aug 2002
PITTSBURGH UNIV PA
Pagination or Media Count:
This project is evaluating whether oral contraceptives and parity are as protective against ovarian cancer in BRCA12 carriers as they are for women in general. It is also determining whether there are survival differences between BRCA12 carriers with ovarian cancer compared to women with sporadic disease. The study employs a case-case design. We will identify about 400 Jewish women with epithelial ovarian cancer. We will genotype these women for the 3 BRCA12 mutations found in Ashkenazi women. We will then compare oral contraceptive use and parity between carriers and non-carriers. We will also compare survival differences between the two groups. In the second year of the project, we identified 242 Jewish women with invasive epithelial ovarian cancer for whom BRCA12 genotyping data was available or was obtained by our assay. We then compared OC use and reproductive factors for those women with and without a mutation. Initial results suggest that OC use, childbearing and breastfeeding are as protective in BRCA12 carriers as they are in women in general. A manuscript detailing these findings is under review.
- Anatomy and Physiology
- Medicine and Medical Research